These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 7883791)
21. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain. Sánchez B; Robledo M; Biarnes J; Sáez ME; Volpini V; Benítez J; Navarro E; Ruiz A; Antiñolo G; Borrego S J Med Genet; 1999 Jan; 36(1):68-70. PubMed ID: 9950371 [TBL] [Abstract][Full Text] [Related]
22. Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. Borst MJ; VanCamp JM; Peacock ML; Decker RA Surgery; 1995 Apr; 117(4):386-91. PubMed ID: 7716719 [TBL] [Abstract][Full Text] [Related]
23. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703 [TBL] [Abstract][Full Text] [Related]
24. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase. Marshall GM; Peaston AE; Hocker JE; Smith SA; Hansford LM; Tobias V; Norris MD; Haber M; Smith DP; Lorenzo MJ; Ponder BA; Hancock JF Cancer Res; 1997 Dec; 57(23):5399-405. PubMed ID: 9393766 [TBL] [Abstract][Full Text] [Related]
25. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192 [TBL] [Abstract][Full Text] [Related]
26. Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. Romeo G; Ceccherini I; Celli J; Priolo M; Betsos N; Bonardi G; Seri M; Yin L; Lerone M; Jasonni V; Martucciello G J Intern Med; 1998 Jun; 243(6):515-20. PubMed ID: 9681852 [TBL] [Abstract][Full Text] [Related]
27. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Blaugrund JE; Johns MM; Eby YJ; Ball DW; Baylin SB; Hruban RH; Sidransky D Hum Mol Genet; 1994 Oct; 3(10):1895-7. PubMed ID: 7849720 [No Abstract] [Full Text] [Related]
28. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515 [TBL] [Abstract][Full Text] [Related]
29. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Santoro M; Carlomagno F; Romano A; Bottaro DP; Dathan NA; Grieco M; Fusco A; Vecchio G; Matoskova B; Kraus MH Science; 1995 Jan; 267(5196):381-3. PubMed ID: 7824936 [TBL] [Abstract][Full Text] [Related]
30. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Acton DS; Velthuyzen D; Lips CJ; Höppener JW Oncogene; 2000 Jun; 19(27):3121-5. PubMed ID: 10871866 [TBL] [Abstract][Full Text] [Related]
31. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects. Beldjord C; Desclaux-Arramond F; Raffin-Sanson M; Corvol JC; De Keyzer Y; Luton JP; Plouin PF; Bertagna X J Clin Endocrinol Metab; 1995 Jul; 80(7):2063-8. PubMed ID: 7608256 [TBL] [Abstract][Full Text] [Related]
32. Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations. Takahashi M; Asai N; Iwashita T; Murakami H; Ito S Recent Results Cancer Res; 1998; 154():229-36. PubMed ID: 10027003 [TBL] [Abstract][Full Text] [Related]
34. Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease. Arighi E; Popsueva A; Degl'Innocenti D; Borrello MG; Carniti C; Perälä NM; Pierotti MA; Sariola H Mol Endocrinol; 2004 Apr; 18(4):1004-17. PubMed ID: 14715928 [TBL] [Abstract][Full Text] [Related]
35. Absence of MEN2A- or 2B-type RET mutations in primary neuroblastoma tumour tissue. Peaston AE; Camacho ML; Norris MD; Haber M; Marsh DJ; Robinson BG; Hyland VJ; Marshall GM Mol Cell Probes; 1998 Aug; 12(4):239-42. PubMed ID: 9727201 [TBL] [Abstract][Full Text] [Related]
36. Multiple endocrine neoplasia type 2: recent progress in diagnosis and management. Heshmati HM; Hofbauer LC Eur J Endocrinol; 1997 Dec; 137(6):572-8. PubMed ID: 9437218 [No Abstract] [Full Text] [Related]
37. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations. Kambouris M; Jackson CE; Feldman GL Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338 [TBL] [Abstract][Full Text] [Related]
38. The RET C620S mutation causes multiple endocrine neoplasia type 2A (MEN2A) but not Hirschsprung disease (HSCR) in a family cosegregating both phenotypes. Fernández RM; Antiñolo G; Eng C; Borrego S Hum Mutat; 2003 Nov; 22(5):412-5. PubMed ID: 14517954 [No Abstract] [Full Text] [Related]
39. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers]. Sansó G; Domené HM; Iorcansky S; Barontini M Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252 [TBL] [Abstract][Full Text] [Related]
40. Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. Eng C N Engl J Med; 1996 Sep; 335(13):943-51. PubMed ID: 8782503 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]